The supplement industry's peptide marketing problem — separating biology from claims

The regulatory structure that enables this is more than thirty years old. The Dietary Supplement Health and Education Act of 1994 — DSHEA — established the framework that allows supplement manufacturers to sell products without FDA premarket approval, provided they make "structure/function claims" rather than drug claims. A structure/function claim says something like "supports joint health" or "promotes skin elasticity" or "helps maintain healthy levels already in normal range." A drug claim says "treats arthritis" or "reduces wrinkles" or "lowers elevated cortisol." The FDA distinguishes between them. Supplement manufacturers walk that line carefully, sometimes on the right side of it, sometimes not, but the essential point is that under DSHEA, a supplement can reach the market without any clinical trial, without any FDA review, and without any demonstrated efficacy, as long as it carries a structure/function claim and the now-familiar disclaimer that the FDA hasn't evaluated the claim.

This regulatory scaffolding is the foundation on which a significant portion of the "peptide supplement" market has been built. And the word "peptide" is doing specific marketing work in that context.

Peptides are real. The research on therapeutic peptides is real — there are dozens of FDA-approved peptide drugs, and hundreds more in clinical development. The mechanisms are not invented. But "peptide" has also become a marketing category that can be borrowed loosely across products where the connection to the compelling peptide science is tenuous at best. A powder containing "collagen peptides," a capsule with "bioactive peptides," a serum with "signal peptides" — these are all technically peptides, but the clinical relevance varies enormously, and the marketing language rarely pauses to distinguish between them.

The collagen peptide category is worth looking at in detail because it represents the honest middle of what the supplement peptide market actually looks like: some real evidence, significant marketing inflation, and an industry that's learned to construct claims that outrun the data.

Hydrolyzed collagen peptides — short amino acid chains derived from collagen — have been studied for their effects on skin hydration, elasticity, and density, as well as joint and bone health in certain populations. The evidence is modest but real. Randomized trials in older women have shown statistically significant improvements in skin elasticity and hydration with oral collagen peptide supplementation at doses around 2.5 to 10 grams daily, with effects that exceed placebo. Some studies in athletes and older adults have shown benefits for joint pain and mobility. These are real findings from real trials with real methodology.

What the marketing does with that evidence is another matter. The modest effect sizes get translated into transformation language. Studies conducted in specific populations — older women with measurably reduced skin collagen, for instance — get generalized to everyone. Findings from a single well-designed trial get expanded into the plural "studies show." The mechanism — providing amino acid substrate, particularly glycine, hydroxyproline, and proline, that may support the body's own collagen synthesis — gets compressed into language suggesting that you're directly rebuilding your joints or skin rather than providing nutritional support for a process the body performs. The result is a category where real biology underpins the products but the marketing consistently positions effects well beyond what the evidence supports.

Other peptide supplement categories are further from the evidence base. The "peptide" that appears in a face cream as a "signal peptide" may have some data from cell culture studies and limited in-vitro evidence, but the translation from a cell culture result to a meaningful clinical effect in a human face has not been made. This is not a secret — the beauty industry publishes mechanisms plausibly — but the inferential distance between "in cell culture, this peptide fragment upregulated collagen synthesis genes" and "this cream makes a measurable difference to your skin" is enormous, and the marketing doesn't acknowledge it.

The influencer layer complicates the picture further. Peptide supplements — and the term is being used loosely enough now to include everything from collagen powders to proprietary "peptide blends" in pre-workout formulations to multi-ingredient longevity stacks — are heavily marketed through influencers whose relationship to the evidence is generally limited to the brand's talking points. "Doctor-recommended" can mean a practitioner with no relevant specialist training reviewed the product for a consulting fee. "Research-backed" can mean the company has collected published papers about the compound category, not papers about their specific product. "Clinically proven" should mean the specific product was tested in a clinical trial and demonstrated statistically significant efficacy — but in supplement marketing, the phrase frequently traces back to research on a different product, a different dose, or a different population.

The honest middle isn't that all supplement peptide marketing is fraud. It's that the incentive structure of the supplement market — where the cost of clinical trials is high, the regulatory barrier to making claims without trials is low, and consumer attention is responsive to scientific-sounding language — produces a systematic drift toward overclaiming. Companies that want to do right by the evidence and companies that don't are competing on the same terms, in the same market, with the same vocabulary. The consumer reading a product page has almost no information to distinguish between them from the marketing alone.

Knowing how to evaluate the claims is more useful than a general skepticism. The questions that actually separate credible evidence from borrowed authority are specific. What is the compound? Not the category but the specific molecule or peptide. Collagen peptides, palmitoyl pentapeptide-4, BPC-157, AOD-9604, semaglutide — these are meaningfully different things with different evidence bases and different regulatory statuses, and the same marketing language can be applied to any of them. What is the dose? Many supplement products include compounds at doses well below what the research used, either to hit a price point or to be able to include the ingredient on the label. A product that contains collagen peptides at 300 milligrams per serving while the trials showing efficacy used 2.5 to 10 grams daily is technically a collagen peptide product but not a dose with evidence behind it. What is the actual study? Not "research shows" but: which study, which journal, what population, what methodology, what endpoint, what effect size? If the brand can't or won't provide this, the claim is essentially unverifiable.

The distinction between a structure/function claim and an evidence-supported clinical claim also tells you something. A brand that says "supports skin elasticity" is operating within the DSHEA framework, making a legally permissible claim that doesn't require evidence. A brand that says "in a randomized controlled trial of 105 postmenopausal women, 10g daily for 24 weeks improved skin elasticity by 9% versus placebo (p<0.05)" is making a specific, verifiable claim. The second type of language is rarer in supplement marketing because it's harder to produce and invites scrutiny. Its presence is a signal. Its absence isn't conclusive — a legitimate product might simply have unsophisticated marketing — but a company that has genuine evidence tends to be specific about it because the specificity is a competitive advantage.

The supplement peptide space is not going to converge on pharmaceutical-grade evidentiary standards. The regulatory architecture doesn't require it and the market economics don't reward it reliably. What the buyer can do is enter it with a calibrated skepticism: real peptide biology exists, the supplement market borrows its vocabulary, and the gap between the two is variable, often large, and almost never disclosed in the marketing. Reading claims for their specific, verifiable content — and noticing what the marketing declines to make specific — is the most useful filter available.